Atlas Trials

A First-in-human Study to Assess OT-C001 (Amplified/Activated Allogenic Natural Killer Cells) in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma

Clinical trial NCT07044050 · RECRUITING

Trial details

NCT number
NCT07044050
Sponsor
Emercell SAS
Status
RECRUITING
Phase
Phase 1
Study type
INTERVENTIONAL
Diffuse Large B-cell Lymphoma With no Other Specification
Start date
2025-06-10
Primary completion
2026-09-30
Enrollment
10

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.